Edwards Lifesciences (NYSE:EW) Posts Quarterly Earnings Results, Misses Expectations By $0.04 EPS

Edwards Lifesciences (NYSE:EW) announced its quarterly earnings results on Tuesday. The medical research company reported $0.58 earnings per share for the quarter, missing the consensus estimate of $0.62 by ($0.04), FiscalAI reports. Edwards Lifesciences had a return on equity of 14.70% and a net margin of 23.25%.The company had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. During the same period in the prior year, the business posted $0.59 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.3% on a year-over-year basis. Edwards Lifesciences updated its Q1 2026 guidance to 0.700-0.760 EPS.

Here are the key takeaways from Edwards Lifesciences’ conference call:

• Edwards reported a strong quarter and year with Q4 sales of $1.57 billion (+11.6%) and full?year growth of 10.7%, and management said it has increased confidence in its 2026 guidance of 8%–10% sales growth and EPS of $2.90–$3.05; the company also holds ~ $3 billion cash and ~$2 billion remaining buyback authorization.
• TAVR remains the primary growth engine: SAPIEN TAVR sales were $1.16 billion (+10.6%) supported by long?term PARTNER 3/2 durability data and the Early TAVR evidence, and a CMS NCD reconsideration (draft expected in June, possible final in Q4) could be a material access tailwind.
• TMTT continues rapid expansion, rising >40% to $156 million (and >$1 billion for the year) as SAPIEN M3 begins rollout, EVOQUE scales, and next?gen PASCAL (including tricuspid) is expected in Q4 — supporting management’s $2 billion by 2030 target.
• Management increased Q4 SG&A by roughly $112 million to fund patient?access initiatives and the AHA partnership, which contributed to a lower?than?expected adjusted EPS of $0.58 (GAAP $0.11 including one?time charges); company says spending was partly delayed and will moderate in 2026.
• Longer?term catalysts include lifetime?management positioning (valve selection strategy), the PROGRESS moderate?AS trial results (to be presented at TCT) and a planned preliminary surgical LAAC introduction later this year, but clinical/readout uncertainty leaves the timing and magnitude of upside unclear.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded up $0.20 during mid-day trading on Tuesday, hitting $77.00. 6,543,660 shares of the company traded hands, compared to its average volume of 4,197,906. Edwards Lifesciences has a one year low of $65.94 and a one year high of $87.89. The stock has a fifty day moving average price of $83.98 and a 200-day moving average price of $81.16. The stock has a market cap of $44.68 billion, a price-to-earnings ratio of 33.19, a price-to-earnings-growth ratio of 3.03 and a beta of 0.94. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.29 and a current ratio of 4.00.

Insider Activity

In other news, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Friday, January 9th. The stock was sold at an average price of $85.70, for a total value of $87,328.30. Following the completion of the transaction, the vice president owned 22,002 shares of the company’s stock, valued at approximately $1,885,571.40. This represents a 4.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Donald E. Bobo, Jr. sold 11,340 shares of the stock in a transaction on Tuesday, January 6th. The shares were sold at an average price of $85.66, for a total value of $971,384.40. Following the sale, the vice president owned 31,870 shares in the company, valued at approximately $2,729,984.20. This represents a 26.24% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 43,804 shares of company stock valued at $3,699,082. Insiders own 0.34% of the company’s stock.

Hedge Funds Weigh In On Edwards Lifesciences

Institutional investors have recently added to or reduced their stakes in the stock. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its stake in shares of Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares during the last quarter. Viking Global Investors LP purchased a new position in Edwards Lifesciences in the 3rd quarter worth approximately $238,688,000. AQR Capital Management LLC boosted its position in Edwards Lifesciences by 114.5% in the 3rd quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company’s stock valued at $161,055,000 after buying an additional 1,111,139 shares during the last quarter. Man Group plc boosted its stake in shares of Edwards Lifesciences by 73.9% during the 2nd quarter. Man Group plc now owns 1,653,939 shares of the medical research company’s stock valued at $129,355,000 after buying an additional 702,712 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its holdings in Edwards Lifesciences by 92.8% in the second quarter. Adage Capital Partners GP L.L.C. now owns 873,817 shares of the medical research company’s stock worth $68,341,000 after purchasing an additional 420,551 shares during the period. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently weighed in on EW shares. Royal Bank Of Canada lifted their target price on shares of Edwards Lifesciences from $95.00 to $100.00 and gave the company an “outperform” rating in a report on Friday, December 5th. Robert W. Baird set a $90.00 target price on Edwards Lifesciences in a research report on Monday, January 12th. Truist Financial set a $92.00 target price on shares of Edwards Lifesciences and gave the company a “hold” rating in a report on Friday, December 5th. UBS Group reiterated a “neutral” rating and set a $94.00 price objective on shares of Edwards Lifesciences in a research report on Wednesday, February 4th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Edwards Lifesciences in a report on Wednesday, January 21st. Three research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $96.77.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.